Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Director | June 09, 2026 | June 11, 2026 |
| Electra Therapeutics, Inc.ETRA · Entity 9265 | Director | September 18, 2026 | September 18, 2026 |
| MACROGENICS INCMGNX · Entity 6104 | Director | May 16, 2019 | May 20, 2019 |
| Neumora Therapeutics, Inc.NMRA · Entity 6115 | Director | May 27, 2026 | May 29, 2026 |
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | Director | May 14, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,188 |
Reported balance
After 2026-06-09 transaction · row 1
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 12,000 · Balance 30,188 F1: These restricted stock units shall vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units shall vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
Electra Therapeutics, Inc.
Report date September 18, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2033-11-16 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: 1/4th of the total shares subject to this option vested one year after October 16, 2023, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.96 · Expires 2036-02-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: 1/48th of the total shares subject to this option shall vest monthly commencing from February 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2036-09-16 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: The shares subject to this option shall vest on the earlier of September 17, 2027 and the date of the next annual meeting of the Issuer's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4th of the total shares subject to this option vested one year after October 16, 2023, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
F2: 1/48th of the total shares subject to this option shall vest monthly commencing from February 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
F3: The shares subject to this option shall vest on the earlier of September 17, 2027 and the date of the next annual meeting of the Issuer's stockholders.
MACROGENICS INC
Report date May 16, 2019 · Filed May 20, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2029-05-16 | Direct | 10,000 |
Reported balance
After 2019-05-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-16 · Grant · Acquired 10,000 · Balance 10,000 F1: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.
Neumora Therapeutics, Inc.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2036-05-26 | Direct | 80,000 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 80,000 · Balance 80,000 F1: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026.
Ultragenyx Pharmaceutical Inc.
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,696 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 7,751 · Balance 33,696 F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.80 · Expires 2036-05-14 | Direct | 14,058 |
Reported balance
After 2026-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-14 · Grant · Acquired 14,058 · Balance 14,058 F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.
F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Crinetics Pharmaceuticals, Inc.
Report date September 01, 2026 · Filed September 01, 2026
Section 16 reporting ended · disclosed 2026-09-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-01 · Disposition to issuer · Disposed 22,836 · Balance 5,925 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). Row 2 · 2026-09-01 · Disposition to issuer · Disposed 5,925 · Balance 0 F2: The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.91 · Expires 2028-03-16 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-01 · Disposition to issuer · Disposed 2,092 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.32 · Expires 2033-06-15 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-01 · Disposition to issuer · Disposed 17,500 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.71 · Expires 2034-06-07 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-01 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.33 · Expires 2035-06-11 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-01 · Disposition to issuer · Disposed 10,350 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.87 · Expires 2036-06-18 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-01 · Disposition to issuer · Disposed 9,730 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration").
F2: The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding.
F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.
F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.
Dermira, Inc.
Report date February 20, 2020 · Filed February 25, 2020
Section 16 reporting ended · disclosed 2020-02-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 1
1 source rowRow 1 · 2020-02-20 · Disposition to issuer · Disposed 5,051 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.51 · Expires 2024-06-05 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-20 · Disposition to issuer · Disposed 14,224 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2025-06-10 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-20 · Disposition to issuer · Disposed 10,344 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.82 · Expires 2026-06-20 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-02-20 · Disposition to issuer · Disposed 10,344 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.01 · Expires 2027-06-12 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.95 · Expires 2028-06-12 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.38 · Expires 2029-06-03 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-02-20 · Disposition to issuer · Disposed 3,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2018 Filed Jun 18, 2018 20:24 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $45.65 | $0.00 |
DisclosureSEC source: 0001209191-18-038302 · doc4.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2025-06-13 F2 · derivative.exercise_date: The option shall vest on June 14, 2019, subject to the Reporting Person's continuous service. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:24 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038302 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,854 F1 · shares: These restricted stock units shall vest on June 14, 2019, subject to the Reporting Person's continuous service. Read SEC document |
| June 13, 2018 Filed Jun 14, 2018 21:45 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionRestricted Stock Unit · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003004 · primarydocument.xml · derivative · entry 4 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F5 · derivative.exercise_date: The RSU, which was granted on June 13, 2017, fully vested on June 13, 2018. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock. Read SEC document |
| June 13, 2018 Filed Jun 14, 2018 21:45 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003004 · primarydocument.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,051 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Represents shares acquired upon vesting of RSU granted on June 13, 2017. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 21:45 UTC | Dermira, Inc. DERM · Entity 11896 | GrantRestricted Stock Unit · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003004 · primarydocument.xml · derivative · entry 3 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F4 · derivative.exercise_date: The RSU will vest 100% of the shares on June 12, 2019, subject to the continuing service of the Reporting Person on such vesting date. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 21:45 UTC | Dermira, Inc. DERM · Entity 11896 | GrantDirector Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0001562180-18-003004 · primarydocument.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-06-12 F2 · derivative.exercise_date: The stock option will vest and become exercisable as to 100% of the shares on June 12, 2019, subject to the continuing service of the Reporting Person on such vesting date. Read SEC document |
| May 30, 2018 Filed May 30, 2018 23:26 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 6,319 | $72.00 | $454,969.26 |
DisclosureSEC source: 0001209191-18-034278 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 17, 2018 Filed May 21, 2018 20:52 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $21.34 | $0.00 |
DisclosureSEC source: 0001125345-18-000068 · wf-form4_152693596609406.xml · derivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-05-17 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| May 15, 2018 Filed May 17, 2018 00:40 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 534 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030726 · doc4.xml · derivative · entry 3 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 534 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F4 · derivative.exercise_date: The restricted stock units ("RSUs") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 14, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F5 · derivative.expiration_date: The earlier of (i) March 27, 2021 or (ii) the recipient's termination date. Read SEC document |
| May 15, 2018 Filed May 17, 2018 00:40 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 534 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030726 · doc4.xml · nonDerivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Shares issued upon settlement of vested restricted stock units. Read SEC document |
| May 14, 2018 Filed May 17, 2018 00:40 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 12,286 | $43.57 | $535,301.02 |
DisclosureSEC source: 0001209191-18-030726 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,820 F1 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $43.25 to $43.85. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range Read SEC document |
| February 15, 2018 Filed Feb 21, 2018 01:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 1,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011672 · doc4.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534 Underlying: Common Stock · 1,603 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F3 · derivative.exercise_date: The restricted stock units ("RSUs") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 14, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F4 · derivative.expiration_date: The earlier of (i) March 27, 2021 or (ii) the recipient's termination date. Read SEC document |
| February 15, 2018 Filed Feb 21, 2018 01:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 1,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011672 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 23:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 1,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-061604 · doc4.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,137 Underlying: Common Stock · 1,602 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F3 · derivative.exercise_date: The restricted stock units ("RSUs") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 14, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F4 · derivative.expiration_date: The earlier of (i) March 27, 2021 or (ii) the recipient's termination date. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 23:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 1,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-061604 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 21:41 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 1,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-049453 · doc4.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,739 Underlying: Common Stock · 1,603 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F3 · derivative.exercise_date: The restricted stock units ("RSUs") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 14, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F4 · derivative.expiration_date: The earlier of (i) March 27, 2021 or (ii) the recipient's termination date. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 21:41 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 1,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-049453 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,901 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units. Read SEC document |
| June 22, 2017 Filed Jun 22, 2017 23:24 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantEmployee Stock Option (Right to Buy) · Derivative | 3,750 | $0.00 Strike: $65.66 | $0.00 |
DisclosureSEC source: 0001209191-17-041472 · doc4.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires 2027-06-22 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 22, 2018. Read SEC document |
| June 22, 2017 Filed Jun 22, 2017 23:24 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-041472 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,069 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 22, 2018. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 21:11 UTC | Dermira, Inc. DERM · Entity 11896 | GrantRestricted Stock Unit · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-002277 · primarydocument.xml · derivative · entry 3 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F3 · derivative.exercise_date: The RSU will vest 100% of the shares on June 13, 2018, subject to the continuing service of the Reporting Person on such vesting date. F2 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 21:11 UTC | Dermira, Inc. DERM · Entity 11896 | GrantDirector Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $28.01 | $0.00 |
DisclosureSEC source: 0001562180-17-002277 · primarydocument.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-06-12 F1 · derivative.exercise_date: The stock option will vest and become exercisable as to 100% of the shares on June 13, 2018, subject to the continuing service of the Reporting Person on such vesting date. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:26 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 21,500 | $0.00 Strike: $13.20 | $0.00 |
DisclosureSEC source: 0001209191-17-039234 · doc4.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2024-06-08 F2 · derivative.exercise_date: The option shall vest on June 8, 2018, subject to the Reporting Person's continuous service. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:26 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039234 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,298 F1 · shares: These restricted stock units shall vest on June 8, 2018, subject to the Reporting Person's continuous service. Read SEC document |
| May 18, 2017 Filed May 22, 2017 23:01 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $19.57 | $0.00 |
DisclosureSEC source: 0001125345-17-000074 · wf-form4_149549404415241.xml · derivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant. Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:00 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 1,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033201 · doc4.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,342 Underlying: Common Stock · 1,602 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F3 · derivative.exercise_date: The restricted stock units ("RSUs") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 14, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F4 · derivative.expiration_date: The earlier of (i) March 27, 2021 or (ii) the recipient's termination date. Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:00 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 1,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033201 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 01:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 1,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011767 · doc4.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,944 Underlying: Common Stock · 1,603 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F3 · derivative.exercise_date: The restricted stock units ("RSUs") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 14, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F4 · derivative.expiration_date: The earlier of (i) March 27, 2021 or (ii) the recipient's termination date. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 01:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 1,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011767 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:19 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 5,500 | $0.00 Strike: $15.08 | $0.00 |
DisclosureSEC source: 0001209191-17-002051 · doc4.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2024-01-03 F2 · derivative.exercise_date: The option shall vest on June 8, 2017, the date of the Company's annual stockholder meeting, subject to the Reporting Person's continuous service. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:19 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-002051 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,093 F1 · shares: These restricted stock units shall vest on June 8, 2017, the date of the Company's annual stockholder meeting, subject to the Reporting Person's continuous service. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 21:30 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 1,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-150869 · doc4.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,547 Underlying: Common Stock · 1,602 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F3 · derivative.exercise_date: The restricted stock units ("RSUs") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 14, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F4 · derivative.expiration_date: The earlier of (i) March 27, 2021 or (ii) the recipient's termination date. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 21:30 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 1,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-150869 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,093 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.